<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37061149</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-7035</ISSN><JournalIssue CitedMedium="Internet"><Volume>250</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Clinical immunology (Orlando, Fla.)</Title><ISOAbbreviation>Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>CD169 expression on monocytes as a marker for assessing type I interferon status in pediatric inflammatory diseases.</ArticleTitle><Pagination><StartPage>109329</StartPage><MedlinePgn>109329</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2023.109329</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1521-6616(23)00108-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Evaluation of type I interferons (IFNs) in inflammatory or autoimmune diseases is challenging because of their rapid clearance in peripheral blood. The IFN gene expression signature has recently been used to evaluate the IFN status; however, this is often a labor-intensive and time-consuming procedure. Therefore, we assessed the feasibility of measuring expression of an IFN-inducible protein, CD169 (Siglec-1), on monocytes and circulating levels of soluble CD169 as alternative markers for type I IFN status in various pediatric inflammatory diseases.</AbstractText><AbstractText Label="METHODS">Data from flow cytometric analysis of surface CD169 on monocytes and an enzyme-linked immunosorbent assay of soluble CD169 in peripheral blood were compared with serum IFN-&#x3b1; levels in 8 patients with viral infections, 5 with bacterial infections, 10 with systemic lupus erythematosus (SLE), 5 with Kikuchi-Fujimoto disease (KFD), 7 with Kawasaki disease (KD), and 8 with inflammatory bowel disease (IBD), and in 8 healthy controls.</AbstractText><AbstractText Label="RESULTS">Surface CD169 expression was detected mainly on CD14<sup>+</sup> monocytes and was significantly increased in patients with viral infections, SLE, and KFD, but not in patients with bacterial infections, KD, and IBD. There were similar trends for circulating soluble CD169; however, there was a significant increase only in patients with viral infections. Surface CD169 levels were significantly correlated with serum levels of IFN-&#x3b1; and soluble CD169.</AbstractText><AbstractText Label="CONCLUSION">Analysis of CD169 expression on CD14<sup>+</sup> monocytes may be useful for rapid assessment of type I IFN status for differentiation of pediatric inflammatory diseases from type 1 IFN-mediated diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sakumura</LastName><ForeName>Naoto</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Tadafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan. Electronic address: tadafumiy@staff.kanazawa-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Usami</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosono</LastName><ForeName>Yuiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Natsumi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasaki</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wada</LastName><ForeName>Taizo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Immunol</MedlineTA><NlmUniqueID>100883537</NlmUniqueID><ISSNLinking>1521-6616</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C571166">SIGLEC1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001424" MajorTopicYN="Y">Bacterial Infections</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD169</Keyword><Keyword MajorTopicYN="N">Monocytes</Keyword><Keyword MajorTopicYN="N">Soluble CD169</Keyword><Keyword MajorTopicYN="N">Type I interferon</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>15</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37061149</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2023.109329</ArticleId><ArticleId IdType="pii">S1521-6616(23)00108-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>